Evidence map›Paper›PMID 40280967›Full record

ArticleCell death & disease2025

Targeting metabolic vulnerability by combining NAMPT inhibitors and disulfiram for treatment of recurrent ovarian cancer.

Kei Kudo, Yoshimi Endo Greer, Daniel R Crooks, Ye Yang, Jeffrey R Brender, Teruhiko Yoshida, Brittney S Harrington, Rahul Kamdar, Soumya Korrapati, Yusuke Shibuya and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Kei KudoWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Yoshimi Endo GreerWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Daniel R CrooksUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ye YangUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jeffrey R BrenderUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Teruhiko YoshidaKidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Brittney S HarringtonWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rahul KamdarWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Soumya KorrapatiWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Yusuke ShibuyaDepartment of Obstetrics and Gynecology, Division of Gynecologic Oncology, Tohoku University School of Medicine, Miyagi, Japan.
Leah HenegarKaryopharm Therapeutics, Newton, MA, USA.
Jeffrey KoppKidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Takeo FujiiWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3747-2688
Stanley LipkowitzWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. lipkowis@navmed.nci.nih.gov.ORCID http://orcid.org/0000-0002-6103-2255
Christina M AnnunziataWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA. christina.annunziata@cancer.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OV) has the highest mortality rate among gynecological cancers. As OV progresses, tumor cells spread outside the ovaries to the peritoneal and abdominal cavities, forming cell clusters that float in the ascitic fluid caused by peritonitis carcinomatosa, leading to further dissemination and metastasis. These cell clusters are enriched with cancer stem cells (CSCs) which are responsible for treatment resistance, recurrence, and metastasis. Therefore, targeting CSCs is a potentially effective approach for treating OV. However, understanding how CSCs acquire treatment resistance and identifying targets against CSCs remains challenging. In this study, we demonstrate that 3D-spheroids of OV cell lines exhibit higher stemness than conventional adherent cells. Metabolomics profiling studies have revealed that 3D-spheroids maintain a high-energy state through increased glucose utilization in the citric acid cycle (TCA), efficient nucleotide phosphorylation, and elevated phosphocreatine as an energy buffer. We also found that nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme for NAD

Indexed as

CytokinesDisulfiramNeoplasm Recurrence, LocalNicotinamide PhosphoribosyltransferaseOvarian NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceNeoplastic Stem CellsSpheroids, CellularXenograft Model Antitumor AssaysCytokinesDisulfiramNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, human

Identifiers

PMID40280967
PMCPMC12032209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.